Proper detection and accurate characterization of Non-Small Cell Lung Cancer (NSCLC) are an open challenge in the imaging field. Biomedical imaging is fundamental in lung cancer assessment and offers the possibility of calculating predictive biomarkers impacting patients' management. Within this context, radiomics, which consists of extracting quantitative features from digital images, shows encouraging results for clinical applications, but the sub-optimal standardization of the procedure and the lack of definitive results are still a concern in the field. For these reasons, this work proposes the design and development of LuCIFEx, a fully-automated pipeline for non-invasive in-vivo characterization of NSCLC, aiming to speed up the analysis process and enable an early diagnosis of the tumor.LuCIFEx pipeline relies on routinely acquired [18F]FDG-PET/CT images for the automatic segmentation of the cancer lesion, allowing the computation of accurate radiomic features, then employed for cancer characterization through Machine Learning algorithms. The proposed multi-stage segmentation process can identify the lesion with a mean accuracy of 94.2±5.0%. Finally, the proposed data analysis pipeline demonstrates the potential of PET/CT features for the automatic recognition of lung metastases and NSCLC histological subtypes, while highlighting the main current limitations of the radiomic approach.

Download full-text PDF

Source
http://dx.doi.org/10.1109/JBHI.2022.3156984DOI Listing

Publication Analysis

Top Keywords

characterization nsclc
8
lung cancer
8
automation radiomics-based
4
radiomics-based identification
4
characterization
4
identification characterization
4
nsclc
4
nsclc proper
4
proper detection
4
detection accurate
4

Similar Publications

Objective: To evaluate signal transducer and activator of transcription 3 (STAT3) inhibition we conducted a co-clinical trial testing danvatirsen, a STAT3 antisense oligonucleotide (ASO) and checkpoint inhibition in conjunction with preclinical experiments.

Methods And Analysis: Orthotopically implanted pancreatic cancer (pancreatic adenocarcinoma (PDAC)) was treated with STAT3 ASO with immune checkpoint inhibition. Tumour infiltrating immune cell populations were characterised via flow cytometry.

View Article and Find Full Text PDF

Unlabelled: IntroductionAs the U.S. population ages more octogenarians are undergoing surgical resection for lung cancer (LC).

View Article and Find Full Text PDF

Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRAS.

J Med Chem

January 2025

Chief executive officer, Jacobio Pharmaceuticals Group Co., Ltd., Beijing100176, P. R. China.

KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutation is commonly found in non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). Inhibitors that covalently modify the mutated codon 12 cysteine have completed proof-of-concept studies in the clinic. Here, we describe structure-based design and cocrystal-aided drug optimization of a series of compounds with the 1,8-naphthyridine-3-carbonitrile scaffold.

View Article and Find Full Text PDF

Introduction: Immune checkpoint inhibitors (ICI) have improved the therapeutic arsenal in outpatient oncology care; however, data on necessity of hospitalizations associated with immune-related adverse events (irAEs) are scarce. Here, we characterized hospitalizations of patients undergoing ICI, from the prospective cohort study of the immune cooperative oncology group (ICOG) Hannover.

Methods: Between 12/2019 and 06/2022, 237 patients were included.

View Article and Find Full Text PDF

Background: Mutations in STK11, KEAP1, and SMARCA4 predispose to inferior immune checkpoint inhibitor (ICI) efficacy in non-small cell lung cancer (NSCLC), particularly among KRAS-mutant cases. However, the frequency, clinicopathologic features, and clinical impact of deletions in these genes are poorly characterized.

Methods: Clinicopathologic correlates of STK11, KEAP1, and SMARCA4 deletion were analyzed in nonsquamous NSCLCs at Dana-Farber Cancer Institute (DFCI).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!